Loading
A phase 2/3 trial of SHR-8068 in colorectal cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer is a phase 2/3 interventional study registered as NCT07454720 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 165 participants planned, started 2026-03-23 and due to reach its primary completion in 2032-11. Interventions recorded: Adebrelimab in combination with SHR-8068 and chemotherapy, Adebrelimab combined with chemotherapy, Chemotherapy. Conditions listed: Locally Advanced Resectable Rectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals, Colorectal cancer.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Shares SHR-8068, Jiangsu Hengrui Pharmaceuticals.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/